Cabaletta Bio, Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on the 2024 Annual Meeting of Stockholders held by Cabaletta Bio, Inc. on June 3, 2024. The record date for the meeting was April 4, 2024, with 46,804,820 outstanding shares of voting common stock.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance matters and voting results.
Material Changes and Voting Results
Stockholders approved two proposals at the Annual Meeting:
- Proposal 1 (Election of Directors): Catherine Bollard, MBChB, M.D., and Richard Henriques, MBA, were elected as Class II directors for three-year terms.
- Proposal 2 (Auditor Ratification): The appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024, was ratified.
| Proposal | For | Against/Withheld | Abstain | Broker Non-Votes |
|---|---|---|---|---|
| Catherine Bollard | 26,225,488 | 12,001,379 (Withheld) | N/A | 3,172,388 |
| Richard Henriques | 37,806,806 | 433,474 (Withheld) | N/A | 3,158,975 |
| Ernst & Young LLP | 41,355,429 | 38,098 (Against) | 5,728 | 0 |
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Key Facts for Investors to Verify
- Confirmation of the new board composition following the election of Catherine Bollard and Richard Henriques.
- Review of the definitive proxy statement (Schedule 14A) for detailed background on the director nominees and auditor selection.
- Verification of the significant number of votes withheld for Catherine Bollard (approximately 25.6% of votes cast) compared to Richard Henriques.